Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176149 | 0.85 | CYP2C19 (0.52) | CYP2C19GRM1CYP3A4CYP2D6CXCR3 | |
| SCHEMBL3184309 | 0.85 | CYP2C19 (0.52) | CYP2C19GRM1CYP3A4CYP2D6CXCR3 | |
| SCHEMBL3621236 | 0.84 | POLB (0.52) | MAP4K4GPR119POLB | |
| SCHEMBL23602022 | 0.82 | MAP4K4 (0.53) | MAP4K4HDAC1GPR119GRM1POLB | |
| SCHEMBL15006962 | 0.78 | GPR119 (0.59) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL16236440 | 0.78 | GPR119 (0.59) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL20139355 | 0.78 | GPR119 (0.59) | MAP4K4HDAC1GPR119GRM1SUV39H2 | |
| SCHEMBL3220338 | 0.77 | PIM1 (0.50) | MAP4K4 | |
| SCHEMBL27788103 | 0.77 | FLT3 (0.37) | CYP2C19GPR119POLB | |
| SCHEMBL12100833 | 0.76 | GRM1 (0.64) | MAP4K4HDAC1GPR119GRM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010008832-A1 | PYRROLO-PYRIDINE-3-YL-PIPERAZINE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016297-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016297-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR3A | MAP4K4 3058/4885CYP2C19 319/4885HDAC1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.